Summary
CSF beta-glucuronidase, polyamines and carcinoembryonic antigen (CEA) were analyzed in 16 patients with meningeal carcinomatosis from solid tumor in systemic organs, 27 with benign brain lesions, 18 with primary brain tumors, 14 with metastatic brain tumors and 5 with leptomeningeal dissemination of other malignant diseases. Beta-glucuronidase levels in all cases of meningeal carcinomatosis, meningeal gliomatosis and meningeal lymphoma were higher than 100 μg/dl/hr; on the other hand, levels in all cases of benign brain lesions were below 100 μg/dl/hr. Levels of beta-glucuronidase and polyamines were not high in the cases with positive cytology after tumor resection. Polyamine levels were below 0.05 nmol/ml in all cases after resection of the metastatic brain tumor.
Cystic fluid of malignant tumors showed high levels of beta-glucuronidase and polyamines. On the other hand, the levels of polyamines in the cystic fluid of benign tumor were low, although the levels of beta-glucuronidase were high. Some cases of meningeal carcinomatosis with high levels of serum CEA did not show high levels of CSF CEA. For metastatic brain tumors, the cases with intraparenchymal tumors, especially with dural attachment showed high levels of beta-glucuronidase and CEA preoperatively, but they returned to normal after surgery. In cases of meningeal carcinomatosis treated by intrathecal chemotherapy with methotrexate (MTX) and cytosine arabinoside (Ara-C), CSF beta-glucuronidase reflected the neurological status better than the cell count decreased rapidly following chemotherapy and beta-glucuronidase was considered as a useful CSF marker in cases of meningeal carcinomatosis to monitor the course of the disease. The same situation was observed in CSF CEA and CEA was also considered as a useful marker when CEA levels in CSF are higher than those in serum.
Similar content being viewed by others
References
Jaeckle KA: Assessment of tumor markers in cerebrospinal fluid. Clinics in Laboratory Medicine 5: 303–315, 1985
Wasserstrom WR, Schwartz MK, Fleisher M, Posner JB: Cerebrospinal fluid biochemical markers in the central nervous system tumors: a review. Ann Clinical Lab Sci 11: 239–251, 1981
Schold SC, Wasserstrom WR, Fleisher M, Schwartz MK, Posner JB: Cerebrospinal fluid biochemical markers of central nervous system metastases. Ann Neurol 8: 597–604, 1980
Shuttleworth E, Allen N: CSF -glucuronidase assay in the diagnosis of neoplastic meningitis. Arch Neurol 37: 684–687, 1980
Van Zanten AP, Twijinstra A, Van Benthem V, Hart AAM, Ongerboer de Viser BW: Cerebrospinal fluid β-glucuronidase activities in patients with central nervous system metastases. Clinica Chimica Acta 147: 127–134, 1985
Albright AL, Marton LJ, Lubich WP, Reigel DH: CSF polyamines in childhood. Arch Neurol 40: 237–240, 1983
Edwards MSB, Davis RL, Laurent JP: Tumor markers and cytologic features of cerebrospinal fluid. Cancer 56: 1773–1777, 1985
Marton LJ, Edwards MS, Levin VA, Lubich WP, Wilson CB: Predictive value of cerebrospinal fluid polyamines in medulloblastoma. Cancer Res 39: 993–997, 1979
Takaue Y, Nishioka K, Van Eys J: Evaluation of polyamine levels in cerebrospinal fluid of children with brain tumors. J Neuro-Oncol 3: 327–333, 1986
Moulinoux JP, Quemener V, LeCalve M, Chatel M, Darcel F: Polyamines in human brain tumors. J Neuro-Oncol 2: 153–158, 1984
Pierangeli E, Occhiogrosso M, Vailati G: Polyamines: Current review and their perspectives in neurosurgery. J Neurosurg Sci 26: 209–211, 1982
Abe K, Hori T: Determination of polyamines in human urine by high-performance liquid chromatography with fluorescence detection. Jap J Clin Chem 14: 315–320, 1985
Kremzner LT, Barrett RE, Terrano MJ: Polyamine metabolism in the central and peripheric nervous system. Ann NY Acad Sci 171: 735–748, 1970
Goldman SS, Volkow ND, Brodie J, Flamm ES: Putrescine metabolism in human brain tumors. J Neuro-Oncol 4: 23–29, 1986
Harik SI, Wehle SU, Sutton CH: Putrescine, a marker for malignant brain tumors. Neurology 28: 351, 1978
Harik SI, Sutton CH: Putrescine as a marker of malignant brain tumors. Cancer Res 39: 5010–5015, 1979
Marton LJ, Heby O, Wilson CB: Increased polyamine concentrations in the cerebrospinal fluid of patients with brain tumors. Int J Cancer 14: 731–735, 1974
Marton LJ, Heby O, Levin VA, Lubich WP, Crafts DC, Wilson CB: The relationship of polyamines in cerebrospinal fluid to the presence of central nervous system tumors. Cancer Res 36: 973–977, 1976
Campbell RA, Morris DR, Bartos D, Daves GD, Bartos F: Advances in polyamine research. Vol 2, Raven Press, New York, 1978
Allen N, Reagan E, Hill C: β-glucuronidase activities in cerebrospinal fluid. Arch Neurol 11: 144–154, 1964
Haidukewych D, Rodin E, Schmaltz S: Elevation of β-glucuronidase activity in medicated patients with epilepsy. Therapeutic Drug Monitoring 6: 15–19, 1984
Anlyan AJ, Starr A: β-glucuronidase activity of spinal and ventricular fluids in humans. Cancer 5: 578–580, 1952
Lehrer GM: Beta-glucuronidase in cerebro-spinal fluid of patients with diseases of the nervous system. Trans Amer Neurol Assoc 88: 244–245, 1963
Oda R, Hirose G, Emori T: The cerebrospinal fluid concentrations of β-glucuronidase and β-2-microglobulin in neurological disorders (in Japanese). Brain and Nerve 37: 155–160, 1985
Ongerboer de Visser BW, Van Zanten AP, Twijnstra A, Nooyen WJ, Hart AAM: Sensitivity and specificity of cerebrospinal fluid biochemical markers of central nervous system metastases. Prog Exp Tumor Res 29: 105–115, 1985
Tenhunen R, Iivanainen M, Kovanen J: Cerebrospinal fluid β-2-microglobulin in neurological disorders. Acta Neurol Scand 57: 366–373, 1978
Klee GG, Tallman RD, Goellner JR, Yanagihara T: Elevation of carcinoembryonic antigen in cerebrospinal fluid among patients with meningeal carcinomatosis. Mayo Clin Proc 61: 9–13, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nakagawa, H., Kubo, S., Murasawa, A. et al. Measurements of CSF biochemical tumor markers in patients with meningeal carcinomatosis and brain tumors. J Neuro-Oncol 12, 111–120 (1992). https://doi.org/10.1007/BF00172659
Issue Date:
DOI: https://doi.org/10.1007/BF00172659